NASDAQ:AKER - Akers Biosciences Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$0.26 -0.01 (-3.70 %)
(As of 08/17/2018 01:19 PM ET)
Previous Close$0.26
Today's Range$0.26 - $0.26
52-Week Range$0.12 - $1.82
Volume9,974 shs
Average Volume10.30 million shs
Market Capitalization$25.60 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.2
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ?Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ?Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKER
CUSIPN/A
Phone856-848-8698

Debt

Debt-to-Equity RatioN/A
Current Ratio8.15
Quick Ratio7.44

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.93 million
Price / Sales6.23
Cash FlowN/A
Price / CashN/A
Book Value$0.13 per share
Price / Book2.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,360,000.00
Net Margins-177.15%
Return on Equity-97.33%
Return on Assets-74.17%

Miscellaneous

Employees32
Outstanding Shares94,110,000
Market Cap$25.60 million

Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

How were Akers Biosciences' earnings last quarter?

Akers Biosciences Inc (NASDAQ:AKER) released its quarterly earnings results on Tuesday, August, 14th. The medical instruments supplier reported ($0.02) earnings per share (EPS) for the quarter. The medical instruments supplier earned $0.53 million during the quarter. Akers Biosciences had a negative return on equity of 97.33% and a negative net margin of 177.15%. View Akers Biosciences' Earnings History.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, November, 21st 2018. View Earnings Estimates for Akers Biosciences.

Who are some of Akers Biosciences' key competitors?

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the folowing people:
  • Mr. Richard C. Tarbox III, Interim Non-Exec. Chairman & Sec. (Age 65)
  • Mr. John J. Gormally, CEO & Director (Age 62)
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 62)
  • Mr. Douglas Carrara, Sr. VP of Global Marketing & Commercial Operations
  • Ms. Pamela E. Hibler, VP of Sales & Distribution

Has Akers Biosciences been receiving favorable news coverage?

Media coverage about AKER stock has trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Akers Biosciences earned a news and rumor sentiment score of 0.21 on Accern's scale. They also assigned news articles about the medical instruments supplier an impact score of 46.69 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Akers Biosciences.

Who are Akers Biosciences' major shareholders?

Akers Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.40%). View Institutional Ownership Trends for Akers Biosciences.

Which institutional investors are buying Akers Biosciences stock?

AKER stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Akers Biosciences.

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $0.26.

How big of a company is Akers Biosciences?

Akers Biosciences has a market capitalization of $25.60 million and generates $3.93 million in revenue each year. Akers Biosciences employs 32 workers across the globe.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected]


MarketBeat Community Rating for Akers Biosciences (NASDAQ AKER)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about Akers Biosciences and other stocks. Vote "Outperform" if you believe AKER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Featured Article: Investing in Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.